Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.Jason J. Luke, Georgina V. Long, Michele Del Vecchio et al.|Journal of Clinical Oncology|2023Cited by 18
Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.Georgina V. Long, Paolo A. Ascierto, Jason J. Luke et al.|Journal of Clinical Oncology|2022Cited by 8